164 related articles for article (PubMed ID: 30199702)
1. A β-glucuronidase-responsive albumin-binding prodrug for potential selective kinase inhibitor-based cancer chemotherapy.
Compain G; Oumata N; Clarhaut J; Péraudeau E; Renoux B; Galons H; Papot S
Eur J Med Chem; 2018 Oct; 158():1-6. PubMed ID: 30199702
[TBL] [Abstract][Full Text] [Related]
2. Selective cancer therapy by extracellular activation of a highly potent glycosidic duocarmycin analogue.
Chen KC; Schmuck K; Tietze LF; Roffler SR
Mol Pharm; 2013 May; 10(5):1773-82. PubMed ID: 23448264
[TBL] [Abstract][Full Text] [Related]
3. Benzyl ether-linked glucuronide derivative of 10-hydroxycamptothecin designed for selective camptothecin-based anticancer therapy.
Leu YL; Chen CS; Wu YJ; Chern JW
J Med Chem; 2008 Mar; 51(6):1740-6. PubMed ID: 18318465
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and Antitumor Properties of BQC-Glucuronide, a Camptothecin Prodrug for Selective Tumor Activation.
Prijovich ZM; Burnouf PA; Chou HC; Huang PT; Chen KC; Cheng TL; Leu YL; Roffler SR
Mol Pharm; 2016 Apr; 13(4):1242-50. PubMed ID: 26824303
[TBL] [Abstract][Full Text] [Related]
5. β-Glucuronidase-responsive prodrugs for selective cancer chemotherapy: an update.
Tranoy-Opalinski I; Legigan T; Barat R; Clarhaut J; Thomas M; Renoux B; Papot S
Eur J Med Chem; 2014 Mar; 74():302-13. PubMed ID: 24480360
[TBL] [Abstract][Full Text] [Related]
6. A camptothecin-based, albumin-binding prodrug enhances efficacy and safety in vivo.
Cheng Z; Huang Y; Shen Q; Zhao Y; Wang L; Yu J; Lu W
Eur J Med Chem; 2021 Dec; 226():113851. PubMed ID: 34547508
[TBL] [Abstract][Full Text] [Related]
7. Beta-glucuronidase-mediated drug release.
de Graaf M; Boven E; Scheeren HW; Haisma HJ; Pinedo HM
Curr Pharm Des; 2002; 8(15):1391-403. PubMed ID: 12052215
[TBL] [Abstract][Full Text] [Related]
8. Designing anticancer multitarget metal thiosemicarbazone prodrug based on the nature of binding sites of human serum albumin carrier.
Yang F; Liang H
Future Med Chem; 2018 Aug; 10(16):1881-1883. PubMed ID: 29925269
[No Abstract] [Full Text] [Related]
9. A humanized immunoenzyme with enhanced activity for glucuronide prodrug activation in the tumor microenvironment.
Chen KC; Wu SY; Leu YL; Prijovich ZM; Chen BM; Wang HE; Cheng TL; Roffler SR
Bioconjug Chem; 2011 May; 22(5):938-48. PubMed ID: 21443266
[TBL] [Abstract][Full Text] [Related]
10. Enhancing SN38 prodrug delivery using a self-immolative linker and endogenous albumin transport.
Jiang X; Zhu L; Wei Q; Lu W; Yu J; Zhu S
J Control Release; 2024 May; 369():622-629. PubMed ID: 38604383
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and in vitro evaluation of β-glucuronidase-sensitive prodrug of 5-aminolevulinic acid for photodiagnosis of breast cancer cells.
Herceg V; Adriouach S; Janikowska K; Allémann E; Lange N; Babič A
Bioorg Chem; 2018 Aug; 78():372-380. PubMed ID: 29627657
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
13. New Taxol (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy.
Alaoui AE; Saha N; Schmidt F; Monneret C; Florent JC
Bioorg Med Chem; 2006 Jul; 14(14):5012-9. PubMed ID: 16554162
[TBL] [Abstract][Full Text] [Related]
14. Prodrug Mono Therapy: synthesis and biological evaluation of an etoposide glucuronide-prodrug.
Schmidt F; Monneret C
Bioorg Med Chem; 2003 May; 11(10):2277-83. PubMed ID: 12713838
[TBL] [Abstract][Full Text] [Related]
15. In situ targeted activation of an anticancer agent using ultrasound-triggered release of composite droplets.
Bezagu M; Clarhaut J; Renoux B; Monti F; Tanter M; Tabeling P; Cossy J; Couture O; Papot S; Arseniyadis S
Eur J Med Chem; 2017 Dec; 142():2-7. PubMed ID: 28416362
[TBL] [Abstract][Full Text] [Related]
16. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of self-immolative glucuronide-based prodrugs of a phenol mustard.
Lougerstay-Madec R; Florent JC; Monneret C; Nemati F; Poupon MF
Anticancer Drug Des; 1998 Dec; 13(8):995-1007. PubMed ID: 10335272
[TBL] [Abstract][Full Text] [Related]
18. Specific activation of glucuronide prodrugs by antibody-targeted enzyme conjugates for cancer therapy.
Wang SM; Chern JW; Yeh MY; Ng JC; Tung E; Roffler SR
Cancer Res; 1992 Aug; 52(16):4484-91. PubMed ID: 1643640
[TBL] [Abstract][Full Text] [Related]
19. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
20. Duocarmycin-based prodrugs for cancer prodrug monotherapy.
Tietze LF; Schuster HJ; Schmuck K; Schuberth I; Alves F
Bioorg Med Chem; 2008 Jun; 16(12):6312-8. PubMed ID: 18524605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]